-VISIT OUR OTHER FORUMS- OB-GYN-L Ultrasound Ultrasound History Fibroid Forum Physicians-in-Training Tech Talk OBSTET-L (portuguese) OBGIN-L (spanish) Nursing

GEN: breast chemoprophylaxis From: art fougner, md (evsono@pipeline.com) Fri Jul 13 11:07:43 2001 Messages sorted by: [ date ][ thread ][ subject ][ author ] Next message: Charlie Chambers: "alopecia" Previous message: art fougner, md: "Re: Teenager at the ER" this from Reuters Canadian groups release guideline on breast cancer chemoprevention Last Updated: 2001-07-12 9:55:44 EDT (Reuters Health) WESTPORT, CT (Reuters Health) - Two Canadian health groups have released a new guideline that should assist women and their physicians in deciding whether tamoxifen and raloxifene treatment is warranted in reducing the risk of breast cancer. Overall, the guideline recommends that for women with a Gail risk assessment index of <1.66% at 5 years, tamoxifen preventive therapy is not recommended. For women with a Gail risk assessment index of 1.66% or greater at 5 years, the pros and cons of tamoxifen preventive therapy need to be discussed. The guideline was produced after a review of relevant literature published between 1966 and 2000, and represents a joint effort by the Canadian Task Force on Preventive Health Care and the Canadian Steering Committee on Clinical Practice Guidelines for the Care and Treatment of Breast Cancer. The groups also addressed two other issues. Based on the current evidence, they conclude that raloxifene probably should not be used for breast cancer prevention outside of the clinical trial setting. While the Gail risk assessment index can be useful in determining whether chemoprevention is warranted, they do not recommend this tool for use by physicians for screening or case finding. Dr. Mark Levine from McMaster University Health Sciences Centre, Hamilton, Ontario, chair of the Steering Committee, and colleagues prepared the guidelines, which appear in the June 12th issue of the Canadian Medical Association Journal. The current guideline is part of a series of breast cancer guidelines produced by the groups. CMAJ 2001;164:1681-1690. -Westport Newsroom 203 319 2700 art -- art fougner, md A series of 1000 cases begins with but a single anecdote. Next message: Charlie Chambers: "alopecia" Previous message: art fougner, md: "Re: Teenager at the ER"

Return to

Mail a New Message to the Forum: ob-gyn-l@obgyn.net Forum Administrator: geffrey.klein@obgyn.net Report Technical Problems: webmaster@obgyn.net Last Updated: Wed Dec 2 04:51:08 2009

The American Medical Association is no longer designating CME hours for AMA Category II CME credit. However, physicians themselves may self designate learning activities as Category II CME credit hours if they feel it is of sufficient educational merit and meets the formal definitions of continuing medical education. OBGYN.net believes these interaction in this forum meets these criteria. For further information see the AMA web site.